Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye

PHASE2CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Dry Eye Syndrome
Interventions
DRUG

EGP-437 with EyeGate® II System

Transscleral iontophoretic delivery of EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) delivered via EyeGate® II Drug Delivery System

DRUG

Sodium citrate buffer solution with EyeGate® II System

Transscleral iontophoretic delivery of sodium citrate buffer solution 100 mM delivered via EyeGate® II Drug Delivery System

Trial Locations (2)

01810

Ophthalmic Research Associates, Andover

01845

Ophthalmic Research Associates, North Andover

Sponsors
All Listed Sponsors
lead

Eyegate Pharmaceuticals, Inc.

INDUSTRY